baber/WOPTO huggingface dataset:
Patent NZ-550784-A (NZ)
Title: Transdermal steroid formulation for osteoporosis
Inventor: MURRAY JAMES ROBERT
IPC: A61K9/70
Filed: 2005-04-28
Abstract: Disclosed is an adhesive patch comprising a substrate, and an adhesive comprising a copolymer of 40-60% by weight methoxyethyl acrylate, 30-40% lauryl acrylate or methacrylate, and 10-25% of a polar monomer, and having a compound of formula (I), or an ester thereof, dispersed in the adhesive, wherein R1-4 are each independently oxo, hydroxy, mercapto, hydrogen, halogen, alkoxy, or aryloxy. Also disclosed is the use of the patch to treat osteoporosis, osteogenesis, neuronal cell death, or ischaemia-induced damage to peripheral organs.
Patent NZ-550792-A (NZ)
Title: Antibacterial compositions
Inventor: KUME HISAE
IPC: A23L33/00
Filed: 2005-03-31
Abstract: Provided is the use of an antibacterial composition in the preparation of a medicament for inhibiting the proliferation of gram-positive bacteria, or both gram-positive and gram-negative bacteria, wherein the composition is (a) prepared using an acidic quark cheese, (b) comprises edible carbohydrates, proteins, and fats, and (c) has a pH of 4.6 or less, and wherein the energy ratio of carbohydrates, proteins, and fats is 50% to 70%, 4% to 25% and 20% to 30%, respectively.
Patent NZ-552056-A (NZ)
Title: Sulfamate and sulfamide derivatives for the treatment of epilepsy and related disorders
Inventor: MCCOMSEY DAVID F
IPC: A61K31/353
Filed: 2005-06-16
Abstract: The disclosure relates to sulfamide and sulfamate derivatives represented by formula (II) and pharmaceutically acceptable salts thereof, wherein the variables are as defined in the specification; pharmaceutical compositions containing them and their use in the treatment of epilepsy and related disorders.
Patent NZ-555470-A (NZ)
Title: Rasagiline orally disintegrating compositions
Inventor: PATASHNIK SHULAMIT
IPC: A61K31/135
Filed: 2005-11-17
Abstract: Disclosed is a solid pharmaceutical composition comprising rasagiline or a pharmaceutical acceptable salt of rasagiline, and particles having a non-filamentous microstructure of at least two sugar alcohols.
Patent NZ-556117-A (NZ)
Title: Stable prostaglandin-containing ophthalmic compositions
Inventor: DEACIUC VICTOR
IPC: A61K31/215
Filed: 2006-01-18
Abstract: Disclosed is a pharmaceutical composition comprising: (a) travoprost at a concentration of 0.002 to 0.008% w/v; (b) a monooleate ester of a polyethoxylated sorbitol (e.g. polysorbate 80) at a concentration of 0.4 to 0.6% w/v; and (c) a pharmaceutically acceptable carrier. This pharmaceutical composition is chemical stabile and is suitable for treating ophthalmic conditions.
Patent NZ-562418-A (NZ)
Title: Ergonomic and adjustable respiratory mask assembly
Inventor: GING ANTHONY
IPC: A62B18/02
Filed: 2003-04-17
Abstract: A nasal mask assembly (10) for nasal CPAP therapy of a patient comprising: (i) a frame (20); (ii) a silicone nasal seal (40) repeatedly attachable to and detachable from the frame; (iii) a rotatable elbow (60) coupled to the frame; (iv) a headgear assembly (80) including relatively flexible headstraps (84), and (v) a stiffening support structure (92) extending from the frame to assist in stabilisation of the nasal seal. The stiffening support structure is made of a relatively rigid material compared to the relatively flexible headstraps. The stiffening support structure has a degree of flexibility in one direction such that variations in patient physiology can be accommodated, the stiffening support structure being stiffer in another direction generally orthogonal to the one direction to resist vertical rotation of the frame.
Patent NZ-573406-A (NZ)
Title: A nucleic acid-polymer particle for and method of tracing movement of a liquid
Inventor: SLEAT ROBERT
IPC: G01P13/00
Filed: 2007-06-18
Abstract: Disclosed is a particle for tagging a material, the particle including: a nucleic acid tag; carrier nucleic acid; and a linear polymer with a backbone including amido and tertiary amino groups arranged regularly on the backbone, wherein the nucleic acid tag and the carrier nucleic acid have different sequences and wherein the particle includes at least ten times more carrier nucleic acid then nucleic acid tag, and wherein the nucleic acid tag and the carrier nucleic acid is encapsulated within the particle. Further disclosed is a method of marking a material including the steps of: i) providing one or more marker particles including a carrier nucleic acid; and ii) applying the marker particles to the material, wherein the marker particles include a linear polymer with a backbone including amido and tertiary amino groups arranged regularly on the backbone and a nucleic acid tag and wherein the nucleic acid tag and the carrier nucleic acid are encapsulated within the one or more marker particles. Further disclosed is the use of a composition including: a carrier nucleic acid, and a linear polymer with a backbone including amido and tertiary amino groups arranged regularly on the backbone and a nucleic acid tag for marking a material, and wherein the nucleic acid tag and the carrier nucleic acid are encapsulated within one or more particles.
Patent NZ-576590-A (NZ)
Title: Tissue targeted antigenic activation of the immune response to treat cancers
Inventor: GUNN HAROLD DAVID
IPC: A61K39/12
Filed: 2007-10-25
Abstract: Provided is a method for formulating an immunogenic composition for treating a melanoma cancer situated in a human patient's skin, comprising: producing an antigenic composition comprising a vaccinia virus; and, formulating the antigenic composition for administration as an immunogenic composition capable of eliciting an immune reaction to treat the melanoma cancer in the human patient. The medicament can be formulated for repeated subcutaneous or intradermal administration.
Patent NZ-578988-A (NZ)
Title: Therapeutic agent for urinary excretion disorder
Inventor: MARUYAMA TAKAYUKI
IPC: A61P43/00
Filed: 2008-02-15
Abstract: Disclosed is the use of an Ep1 antagonist compound of formula (I) in the manufacture of a medicament for prevention, treatment and/or symptom improvement of dysuria, wherein the substituents are as described within the specification . Examples of compounds of formula (I) include: 3-methyl-4-[6-[N-isobutyl-N-(2-thiazolylsulfonyl)amino]indan-5-yloxymethyl]benzoic acid; and 4-[6-[N-isobutyl-N-(4-methyl-2-thiazolylsulfonyl)amino]indan-5-yloxymethyl]benzoic acid.
Patent NZ-579050-A (NZ)
Title: Treatment and prevention of neurodegenerative diseases using gene therapy
Inventor: YOO TAI JUNE
IPC: A61K39/00
Filed: 2008-02-04
Abstract: Disclosed is the use of a composition comprising nucleic acid encoding one or more cytokines that induce a cellular immune response in the manufacture of a medicament for treating or ameliorating Alzheimer's disease in a subject, wherein said one or more cytokines are: (i) IL-10; (ii) a combination of IL-10 and IL-13; or (iii) a combination of IL-10, IL-13 and IL-4, and wherein the nucleic acid does not encode beta-amyloid or beta-amyloid 1-42.
Patent NZ-582626-A (NZ)
Title: Thermostabilization of proteins
Inventor: BRIM REMY L
IPC: A61K38/46
Filed: 2008-07-10
Abstract: Disclosed is a composition comprising a cocaine esterase (CocE) polypeptide; and at least one thermostabilization compound, wherein the CocE in the presence of the compound is more thermostable than the CocE in the absence of the compound; and the one or more thermostabilization compounds as shown in the accompanying figures.
Patent NZ-584271-A (NZ)
Title: Macrophage-stimulating protein receptor (ron) antibodies and methods of treatment thereof
Inventor: PEREIRA DANIEL
IPC: C07K16/00
Filed: 2008-11-21
Abstract: Disclosed is an antibody or fragment thereof that specifically binds to a human RON protein, wherein said antibody or fragment thereof comprises a CDRH1 having a sequence GFTFSSYLMT (SEQ ID NO: 29), a CDRH2 having a sequence NIKQDGSEKYYVDSVKG (SEQ ID NO: 31), a CDRH3 having a sequence DGYSSGRHYGMDV (SEQ ID NO: 33), a CDRL1 having a sequence RASQSVSRYLA (SEQ ID NO: 35), a CDRL2 having a sequence DASNRAT (SEQ ID NO: 37) and a CDRL3 having a sequence QQRSNWPRT (SEQ ID NO: 39). Also disclosed is a use of the antibody or fragment thereof for the manufacture of a medicament for inhibiting angiogenesis, tumor growth, proliferation of tumor cells, migration of tumor cells, invasion of tumor cells, RON activation, or phosphorylation of RON, MAPK and/or Akt.
Patent NZ-586079-A (NZ)
Title: Determining content for inclusion in a broadcast stream based on user preferences received over a separate network
Inventor: PAREKH JATEEN P
IPC: H04N21/475
Filed: 2008-12-22
Abstract: Disclosed is a system for broadcasting a stream of content to users. The system is comprised of a user interface (102) and a social broadcasting server (104). The user interface (102) is configured to receive one or more network communications indicating a preference of the sending user with respect to content of the broadcast stream. The communications are received from each of a plurality of the users at least in part via a network other than the network via which the content is broadcast. The social broadcasting server (104) is configured to process the network communications to determine and update dynamically preferred content and provide the content for inclusion in the broadcast. The preferred content reflects at least in part the network communications received from the plurality of users. Processing the network communications comprises using a rules engine to temper the preference by applying one or more business rules. The one or more business rules comprise governmental restrictions on the frequency with which content is broadcast.
Patent NZ-586286-A (NZ)
Title: Combination compression and impactor rock crushing machine
Inventor: KOSOVICH JOHN
IPC: B02C4/00
Filed: 2010-06-18
Abstract: A rock crushing apparatus. Known apparatus operate on the distinct principles of compression crushing (compression between moving surfaces) or impact crushing (compression via high velocity rock impacting a surface). Both types of apparatus have disadvantages in the quality of the crushed product, energy inefficiency or high rotor wear rates. The apparatus comprises a rotor comprising a number of reciprocating (11) and fixed compression crushing elements (12, 13) to compression crush the rock between adjacent reciprocating and fixed surfaces. The positioning of these elements within the rotor performs an arresting action on the rock to limit the maximum radial velocity (Vr) the rock attains before its ejection from the compression crushing elements for impact crushing on an adjacent surface. In this way the disadvantages of compression and impact crushing are minimised to produce a superior product.
Patent NZ-587100-A (NZ)
Title: Matching call centre agents with callers by using a pattern matching algorithm and determining a probability score
Inventor: XIE QIAOBING
IPC: H04M3/42
Filed: 2009-01-21
Abstract: 587100 Disclosed is a method for routing callers to agents (105) in a call-centre routing environment. Caller data for each of a set of callers is identified by one or more computers. The data includes two or more data elements selected from demographic data and/or psychographic data of the caller. Agent data for a set of agents (105) is identified by the one or more computers, the data including two or more data elements selected from demographic data and/or psychographic data of the agent (105). Using a pattern matching algorithm each agent of the set of agents (105) is matched to each caller of the set of callers. A probability score for an optimal interaction for each match is determined and one of the callers of the set of callers is moved to a queue, moved to a pool, moved to a different position in a queue, placed in a different queue or placed in a different pool of callers. This is based at least in part on the probability scores obtained from the pattern matching algorithm.
Patent NZ-592061-A (NZ)
Title: Secure negotiation of authentication capabilities
Inventor: THAKARE KIRAN
IPC: H04L29/06
Filed: 2009-05-18
Abstract: 592061 Disclosed is a communications network (20). The network includes a server (24) configured to use authentication capabilities information of a terminal (30), or a value derived from the authentication capabilities information, as input to a function to determine a first cryptographic value. The authentication capabilities information provides an indication of authentication capabilities of the terminal (30). An authentication node (22) makes verification of an authentication procedure for the terminal (30) using the first cryptographic value to complete the authentication procedure before security capabilities are used.
Patent NZ-593512-A (NZ)
Title: Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
Inventor: PUSHPALA SHAMIM
IPC: A61K31/4535
Filed: 2009-11-12
Abstract: Disclosed is a packaged solid sufentanil drug dosage form comprising: (a) a solid sufentanil drug dosage form having a mass of from about 2mg to about 25mg or a volume of from about 2mcl to about 25mcl, said tablet comprising; (b) a primary package containing said solid sufentanil drug dosage form and an oxygen scavenger, wherein the percentage of sufentanil oxidative degradation products is minimized or eliminated in a solid sufentanil drug dosage form packaged with said oxygen scavenger relative to a solid sufentanil drug dosage form packaged in the absence of an oxygen scavenger. Also disclosed is a method for preventing oxidative degradation of a solid sufentanil drug dosage form.
Patent NZ-595810-A (NZ)
Title: Quaternary ammonium salt compound
Inventor: SEGAWA KEI
IPC: A61K31/4709
Filed: 2010-04-27
Abstract: A biphenyl ammonium compound represented by formula (I) or a salt thereof, which has a BETA2 adrenergic receptor agonist activity and a muscarin receptor antagonist activity. R1 is H or a C1-8 alkyl. R4 is a C1-10 alkylene. R2 is a single bond, a (substituted) C1-8 alkylene, a C2-4 alkenylene, or an O-(C1-4 alkylene). X is a single bond, O, CONR3, NR3CO, or NR3COCH2O (wherein R3 is H or a C1-8 alkyl). A1 is a single bond, a (substituted) C6-10 arylene, etc. R8 and R9 each is X, CN, a C1-6 alkyl, etc. a and b each is 0-3. W- is an anion. Y is any of formulae (1) to (9). Q is any of formulae (10) to (12) (wherein R6 and R7 each is a (substituted) C1-6 alkyl or a (substituted) C8-10 phenoxyalkyl; n is 0-2; m is 0-3; and R5 is a (substituted) C1-6 alkyl (two of R5 to R8 may form a ring structure)).
Patent NZ-596430-A (NZ)
Title: Method for detecting a wound infection
Inventor: GUBITZ GEORG
IPC: G01N33/52
Filed: 2010-05-18
Abstract: NZ 596430 Disclosed is a method for detecting a wound infection comprising the steps of: contacting a sample obtained from a wound with at least three substrates for at least three enzymes selected from the group consisting of lysozyme, elastase, cathepsin G and myeloperoxidase; and detecting a wound infection when a conversion of the at least three substrates with said at least three enzymes is determined.
Patent NZ-599003-A (NZ)
Title: Dryblended nutritional powders comprising powdered lecithin and powdered carbohydrate
Inventor: MATOVICH ERIC M
IPC: A23L33/00
Filed: 2010-09-16
Abstract: Disclosed is a method of manufacturing a nutritional powder, the method comprising preparing a base nutritional powder; and introducing into the base nutritional powder a carbohydrate and a powdered lecithin.
Patent NZ-602242-A (NZ)
Title: Tibial prosthetic component for a partial or unicondylar bearing knee replacement, and a kit for a surgeon
Inventor: DODD CHRIS
IPC: A61F2/38
Filed: 2011-03-11
Abstract: Disclosed are a tibial prosthetic component for a partial or unicondylar bearing knee replacement, a kit and a prosthetic unicondylar meniscal bearing prosthetic knee. The disclosure notes that tibial prosthetic components are generically sized and are not suitable for smaller patients as more bone of the tibia is required to be removed for the prosthetic to be implanted. The tibial prosthetic component for a partial or unicondylar bearing knee replacement comprises a plate (100) for forming a tibial plateau of a tibia. A peripheral region (120) of the plate (100) has a thickness of less than 3mm.
Patent NZ-621131-A (NZ)
Title: Systems and processes for production of fuel and fuel blends
Inventor: BAUSTIAN JAMES J
IPC: C10L1/32
Filed: 2012-09-21
Abstract: Methods for increasing a distillate product yield from an oil refinery, comprising: (a) operating an oil refinery to produce a light distillate product and a middle distillate product from crude oil, wherein the oil refinery includes a fluid catalytic cracker (FCC) unit; (b) feeding a feedstock to the FCC unit, wherein the feedstock is derived from the crude oil, wherein the FCC unit is operated at a first cut-point temperature to fractionate the feedstock and produce products including a first FCC product and a second FCC product, wherein the light distillate product includes the first FCC product, and wherein the middle distillate product includes the second FCC product; and (c) blending the light distillate product with an amount of butanol to produce a butanol blended gasoline, wherein the FCC unit is operated at a second cut-point temperature when the oil refinery is operated to produce a different light distillate product for blending with an amount of ethanol for producing an automotive-grade blended gasoline, wherein the first cut-point temperature is lower than a second cut-point temperature, wherein an amount of the middle distillate product when the FCC is operated at the first cut-point temperature is greater than an amount of the middle distillate product when the FCC unit is operated at the second cut-point temperature.
Patent NZ-622927-A (NZ)
Title: Composition comprising scirpusin a and scirpusin b anti-obesity potential thereof
Inventor: NAGABHUSHANAM KALYANAM
IPC: A61P3/04
Filed: 2013-07-17
Abstract: Disclosed is an anti-adipogenic/anti-obesity composition comprising the ethyl acetate fraction of the rhizomes of Cyperus rotundus, said ethyl acetate fraction comprising scirpusin A and scirpusin B represented by STR#1 and STR#2 respectively.
Patent NZ-624414-A (NZ)
Title: System for inductively transferring electric energy to a vehicle using consecutive segments
Inventor: NIKLES THOMAS
IPC: H01F38/14
Filed: 2012-11-09
Abstract: Disclosed is a system for transferring electric energy to a vehicle (81), in particular to a track bound vehicle such as a light rail vehicle or to a road automobile. The system comprises an electric conductor arrangement for producing an alternating electromagnetic field and for thereby transferring the energy to the vehicle (81). The conductor arrangement comprises a plurality of consecutive segments (T1, T2, T3) which extend along the path of travel of the vehicle (81). Each segment (T1, T2, T3) includes at least one alternating current line for carrying an alternating current in order to produce the alternating electromagnetic field. The system includes a current supply (108) for supplying electrical energy to the segments (T1, T2, T3),. The segments are electrically connected in parallel to each other and to the current supply (108). For a sequence of consecutive segments, (K1, K2, K3) is assigned and connected to each segment (T1, T2, T3). Each assigned converter (K1, K2, K3) is connected to the current supply (108) and is adapted to convert a current carried by the current supply (108) to an alternating current carried by the at least one alternating current line of the segment (T1, T2, T3) so that there is a sequence of assigned converters (K1, K2, K3) for the corresponding sequence of consecutive segments (T1, T2, T3). Each of the sequence of assigned converters (K1, K2, K3) is connected to a synchronisation link for synchronizing operation of the sequence of assigned converters (K1, K2, K3). The system is adapted to synchronise the sequence of assigned converters (K1, K2, K3) in a manner so that the electromagnetic field produced by the sequence of consecutive segments is continuous at the interface or interfaces between the consecutive segments (T1, T2, T3).
Patent NZ-626473-A (NZ)
Title: Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
Inventor: SANIÈRE LAURENT RAYMOND MAURICE
IPC: C07D471/04
Filed: 2012-12-20
Abstract: A compound according to Formula (Ia) wherein L1, and G, and R1 are as described herein. The present disclosure relates to compounds that antagonize GPR84, a G-protein-coupled receptor that is involved in inflammatory conditions, and methods for the production of these compounds, pharmaceutical compositions comprising these compounds, and methods for the prevention and/or treatment of inflammatory conditions (for example inflammatory bowel diseases (IBD), rheumatoid arthritis, vasculitis, lung diseases (e.g. chronic obstructive pulmonary disease (COPD) and lung interstitial diseases (e.g. idiopathic pulmonary fibrosis (IPF))), neuroinflammatory conditions, infectious diseases, autoimmune diseases, endocrine and/or metabolic diseases, and/or diseases involving impairment of immune cell functions by administering a compound of formula (Ia).
Patent NZ-627579-A (NZ)
Title: Berley dispenser
Inventor: BEVAN RICHARD POTTS
IPC: A01K97/02
Filed: 2014-07-17
Abstract: A collapsible berley dispenser is disclosed. The dispenser comprises a tubular mesh casing fitted to a base affixed to a spiral frame element. The tubular casing is configured to contain berley, or chum, and release the berley, or chum, when submerged in water. The spiral frame element may present in a collapsed configuration when not suspended from a line but will expand when it is suspended from a line, and can be converted by the user from a normally-collapsed configuration to a normally expanded configuration if preferred. Alternatively, the spiral frame element is pitched such that the dispenser remains in an expanded configuration whether or not it is suspended from a line, but is collapsible if required. A tie or clip is further provided for holding the dispenser in a collapsed condition.
Patent NZ-701601-A (NZ)
Title: Anti-gcc antibody molecules and use of same to test for susceptibility to gcc-targeted therapy
Inventor: FRANK HELEN ALISON
IPC: C12N15/10
Filed: 2013-04-27
Abstract: Antibodies and antigen-binding fragments of antibodies that bind GCC are disclosed. The invention also provides diagnostic methods for identifying patients who should receive a GCC-targeted therapy utilizing the anti-GCC antibodies provided herein. The anti-GCC antibody molecules are useful as naked antibody molecules and as components of immunoconjugates. Accordingly, in another aspect, the invention features immunoconjugates comprising an anti-GCC antibody molecule described herein and a therapeutic agent or label. The invention also features methods of using the anti-GCC antibody molecules and immunoconjucates described herein, e.g., for detection of GCC and of cells or tissues that express GCC. Such methods are useful, inter alia, for diagnosis, prognosis, imaging, or staging of a GCC-mediated disease. Accordingly, in some aspects, the invention features methods of identifying a subject for treatment with a GCC- targeted therapy, e.g., an anti-GCC antibody therapy, e.g., an immunoconjugate comprising an anti-GCC antibody conjugated with a therapeutic agent.